TRAV19
T cell receptor alpha variable 19
Also known as: TCRAV12S1, TCRAV19S1, TVA19_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- A0A0A6YYK7
- Gene
- TRAV19
- Ensembl
- ENSG00000211799
- Chromosome
- 14
- Canonical length
- 116 aa
- Protein class
- Predicted intracellular proteins, T-cell receptor genes
- Quaternary structure
- Homodimer
OverviewNCBI Gene
T cell receptors recognize foreign antigens which have been processed as small peptides and bound to major histocompatibility complex (MHC) molecules at the surface of antigen presenting cells (APC). Each T cell receptor is a dimer consisting of one alpha and one beta chain or one delta and one gamma chain. In a single cell, the T cell receptor loci are rearranged and expressed in the order delta, gamma, beta, and alpha. If both delta and gamma rearrangements produce functional chains, the cell expresses delta and gamma. If not, the cell proceeds to rearrange the beta and alpha loci. This region represents the germline organization of the T cell receptor alpha and delta loci. Both the alpha and delta loci include V (variable), J (joining), and C (constant) segments and the delta locus also includes diversity (D) segments. The delta locus is situated within the alpha locus, between the alpha V and J segments. During T cell development, the delta chain is synthesized by a recombination event at the DNA level joining a D segment with a J segment; a V segment is then joined to the D-J gene. The alpha chain is synthesized by recombination joining a single V segment with a J segment. For both chains, the C segment is later joined by splicing at the RNA level. Recombination of many different V segments with several J segments provides a wide range of antigen recognition. Additional diversity is attained by junctional diversity, resulting from the random additional of nucleotides by terminal deoxynucleotidyltransferase. Five variable segments can be used in either alpha or delta chains and are described by TRAV/DV symbols. Several V and J segments of the alpha locus are known to be incapable of encoding a protein and are considered pseudogenes. [provided by RefSeq, Aug 2016]
Canonical amino-acid sequenceUniProt
116 residues, UniProt reviewed canonical sequence.
>A0A0A6YYK7|TRAV19
1 MLTASLLRAV IASICVVSSM AQKVTQAQTE ISVVEKEDVT LDCVYETRDT TYYLFWYKQP
61 PSGELVFLIR RNSFDEQNEI SGRYSWNFQK STSSFNFTIT ASQVVDSAVY FCALSELocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRAV19 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Highest tissue expression
- 34 nTPM
Expression across tissuesHPA
Tissue
- thymus: 34 nTPM
- lymph node: 17 nTPM
- tonsil: 12 nTPM
- spleen: 6.1 nTPM
- appendix: 5.8 nTPM
- stomach: 3.5 nTPM
Single-cell type
- t-cells: 1.1 nCPM
- differentiating spermatogonia: 0.4 nCPM
- early primary spermatocytes: 0.4 nCPM
- undifferentiated spermatogonia: 0.3 nCPM
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
Immune cell
- memory CD8 T-cell: 46 nTPM
- naive CD8 T-cell: 25 nTPM
- T-reg: 24 nTPM
- naive CD4 T-cell: 23 nTPM
- memory CD4 T-cell: 18 nTPM
- total PBMC: 8 nTPM
Brain region
- white matter: 0.3 nTPM
- medulla oblongata: 0.2 nTPM
- pons: 0.2 nTPM
- spinal cord: 0.2 nTPM
- amygdala: 0.1 nTPM
- choroid plexus: 0.1 nTPM
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRAV19 as an antibody target. Whether an autoantibody or antibody against TRAV19 could matter depends on whether native TRAV19 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRAV19 is annotated at the cell surface, where native TRAV19 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TRAV19 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...